Tatsuo Hosoya
Jikei University School of Medicine
Internal medicineUrologyEndocrinologySurgeryPathologyRenal functionChemistryHemodialysisKidney diseasePeritoneal dialysisHyperuricemiaUric acidKidneyCreatinineGoutNephropathyNephrologyMedicineBiologyGastroenterology
433Publications
55H-index
7,650Citations
Publications 438
Newest
#1Toshinari Takahashi (Mochida Pharmaceutical Co., Ltd)
Last. Tatsuo Hosoya (Jikei University School of Medicine)H-Index: 55
view all 0 authors...
Background: Hyperuricemia is a risk factor for the development of hypertension and is comorbid in many hypertensive patients. According to Japanese hypertension management guidelines published in 2019, a target serum uric acid level of ≤6.0 mg/dL is recommended in hypertensive patients with gout or asymptomatic hyperuricemia. Dotinurad is a novel uric acid-lowering drug classified as a selective urate reabsorption inhibitor. A pooled analysis was performed on the uric acid-lowering effect of dot...
Source
#1Toshinari Takahashi (Mochida Pharmaceutical Co., Ltd)
Last. Tatsuo Hosoya (Jikei University School of Medicine)H-Index: 55
view all 4 authors...
Dotinurad is a selective urate reabsorption inhibitor (SURI), which selectively inhibits URAT1 to lower serum uric acid levels in patients with hyperuricemia. Herein, the effects of dotinurad were compared among patient groups with different stages of renal dysfunction. Patient data from four clinical trials were pooled and divided into four groups according to the stage of renal dysfunction to compare the effects of dotinurad at different stages. The grouping (stages G1–G3b) was based on the es...
Source
#1Tomohito GohdaH-Index: 27
#2Naotake YanagisawaH-Index: 17
Last. Naohiko ImaiH-Index: 6
view all 16 authors...
Source
#1Tomohiko IshikawaH-Index: 1
#2Toshinari Takahashi (Mochida Pharmaceutical Co., Ltd)
Last. Tatsuo Hosoya (Jikei University School of Medicine)H-Index: 55
view all 4 authors...
INTRODUCTION Gout is an inflammatory disease triggered by deposition of urate crystals secondary to longstanding hyperuricemia, and its management implies both the treatment of flares and management of hyperuricemia. Dotinurad is a selective urate reabsorption inhibitor (SURI), potently inhibits urate transporter 1 in the apical surface of renal proximal tubular cells, and has been approved for the treatment of gout and hyperuricemia in Japan. AREAS COVERED This overview of dotinurad covers nonc...
Source
#1Akiyoshi Nakayama (National Defense Medical College)H-Index: 23
#2Masahiro Nakatochi (Nagoya University)H-Index: 22
Last. Hirotaka Matsuo (National Defense Medical College)H-Index: 37
view all 54 authors...
OBJECTIVES: Genome-wide meta-analyses of clinically defined gout were performed to identify subtype-specific susceptibility loci. Evaluation using selection pressure analysis with these loci was also conducted to investigate genetic risks characteristic of the Japanese population over the last 2000-3000 years. METHODS: Two genome-wide association studies (GWASs) of 3053 clinically defined gout cases and 4554 controls from Japanese males were performed using the Japonica Array and Illumina Array ...
9 CitationsSource
#1Tatsuo Hosoya (Jikei University School of Medicine)H-Index: 55
#2Takafumi SanoH-Index: 3
Last. Tetsuo OhashiH-Index: 3
view all 5 authors...
Background Dotinurad, a novel selective urate reabsorption inhibitor (SURI), reduces serum uric acid levels by selectively inhibiting urate transporter 1 (URAT1) for the treatment of hyperuricemia with or without gout. We confirmed the serum uric acid lowering effect and safety of dotinurad.
3 CitationsSource
#1Hiroyuki FukaseH-Index: 1
#2Daisuke OkuiH-Index: 2
Last. Tatsuo Hosoya (Jikei University School of Medicine)H-Index: 55
view all 6 authors...
Background Dotinurad, a novel selective urate reabsorption inhibitor, exerts a serum uric acid-lowering effect by selectively inhibiting urate transporter 1 (URAT1) in patients with hyperuricemia. It is generally known that the progression of renal dysfunction is associated with a reduction in the serum uric acid-lowering effects of uricosuric drugs. We, therefore, investigated the pharmacokinetics (PK), pharmacodynamics (PD), and safety of dotinurad in subjects with renal dysfunction.
2 CitationsSource
#1Tatsuo Hosoya (Jikei University School of Medicine)H-Index: 55
#2Masahiko FushimiH-Index: 2
Last. Tetsuo OhashiH-Index: 3
view all 5 authors...
Background Dotinurad is a novel selective urate reabsorption inhibitor (SURI) which reduces serum uric acid levels by selectively inhibiting urate transporter 1 (URAT1). This study was intended to verify the efficacy and safety of dotinurad following treatment for 34 or 58 weeks in hyperuricemic patients with or without gout.
2 CitationsSource
#1Tatsuo Hosoya (Jikei University School of Medicine)H-Index: 55
#2Takafumi SanoH-Index: 3
Last. Tetsuo OhashiH-Index: 3
view all 5 authors...
Background Dotinurad, a novel selective urate reabsorption inhibitor (SURI) that has a future potential for the treatment of hyperuricemia, reduces serum uric acid levels by selectively inhibiting urate transporter 1 (URAT1). We evaluated the efficacy and safety of dotinurad in hyperuricemic Japanese patients with or without gout.
3 CitationsSource
#1Tatsuo Hosoya (Jikei University School of Medicine)H-Index: 55
#2Kazuki Furuno (Mochida Pharmaceutical Co., Ltd)H-Index: 1
Last. Shingo Kanda (Mochida Pharmaceutical Co., Ltd)H-Index: 2
view all 3 authors...
Dotinurad is a novel, selective urate reabsorption inhibitor (SURI), which reduces serum uric acid levels by selective inhibition of the urate transporter 1 (URAT1). The Japanese guideline for the management of hyperuricemia and gout recommends that drug selection should be based on classification of hyperuricemia as a fundamental principle. However, there may be some cases where this principle is not observed. We investigated the pharmacodynamics and safety of dotinurad in outpatients with uric...
Source